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ABSTRACT
Tyrosine kinase inhibitors (TKIs) including axitinib have been introduced in the 
treatment of renal cell carcinoma (RCC) because of their anti-angiogenic properties. 
However, no evidence are presently available on a direct cytotoxic anti-tumor activity 
of axitinib in RCC. 
Herein we reported by western blot analysis that axitinib treatment induces a 
DNA damage response (DDR) initially characterized by γ-H2AX phosphorylation and 
Chk1 kinase activation and at later time points by p21 overexpression in A-498 and 
Caki-2 RCC cells although with a different potency. Analysis by immunocytochemistry 
for the presence of 8-oxo-7,8-dihydro-2’-deoxyguanosine in cellular DNA and flow 
cytometry using the redox-sensitive fluorescent dye DCFDA, demonstrated that DDR 
response is accompanied by the presence of oxidative DNA damage and reactive 
oxygen species (ROS) generation. This response leads to G2/M cell cycle arrest 
and induces a senescent-like phenotype accompanied by enlargement of cells and 
increased senescence-associated β-galactosidase activity, which are abrogated by 
N-acetyl cysteine (NAC) pre-treatment. In addition, axitinib-treated cells undergo to 
cell death through mitotic catastrophe characterized by micronucleation and abnormal 
microtubule assembly as assessed by fluorescence microscopy. 
On the other hand, axitinib, through the DDR induction, is also able to increase 
the surface NKG2D ligand expression. Accordingly, drug treatment promotes NK cell 
recognition and degranulation in A-498 RCC cells in a ROS-dependent manner. 
Collectively, our results indicate that both cytotoxic and immunomodulatory 
effects on RCC cells can contribute to axitinib anti-tumor activity.
INTRODUCTION
Renal cell carcinoma (RCC) accounts for 2-3% of 
all malignancies, with approximately 84,400 new cases 
and 34,700 cancer-related deaths in Europe in 2013 [1]. 
Almost one third of the patients present metastatic disease 
at diagnosis and another 20% develop metastases after 
nephrectomy [2, 3].
Angiogenesis is critical for sustaining RCC growth 
and haematogenous dissemination [4]. Tyrosine kinase 
inhibitors (TKIs) targeting vascular endothelial growth 
factor receptor (VEGFR), such as sunitinib, sorafenib, 
pazopanib and axitinib, the anti-VEGF antibody 
bevacizumab and the mammalian target of rapamycin 
(mTOR) inhibitors everolimus and temsirolimus, have 
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been sequentially approved by the US Food and Drug 
Administration (FDA) [5-12].
Axitinib is a potent and selective inhibitor of 
VEGFR 1, 2, and 3 approved by FDA in 2012 for the 
treatment of patients with metastatic RCC (mRCC) after 
failure of one prior systemic therapy. The European 
Medicines Agency has approved the use of axitinib in 
2015 for the treatment of advanced renal carcinoma after 
failure of prior treatment with sunitinib or interleukin 2 
(IL-2) [13]. Its use as first-line therapy for advanced or 
mRCC was also reported [14, 15].
In experimental models, axitinib produces a dose-
dependent blockade of VEGFR-2 phosphorylation, 
reduction of vascular permeability and angiogenesis, and 
induction of apoptosis, providing evidence for therapeutic 
potential [16]. Moreover, in murine RCC xenografts, 
axitinib augments CD8+ T cell-mediated antitumor activity 
against renal carcinoma via a STAT3-dependent reversal 
of myeloid suppressor cells (MDSC) accumulation in the 
spleens and tumor beds [17]. 
Agents that cause genotoxic stress or DNA-
replication inhibitors have been recently shown to activate 
the DNA damage response (DDR) as well as to increase 
the expression of stress-induced NKG2D and DNAX 
accessory molecule-1 (DNAM-1) ligands recognized 
by the innate immune system [18]. DDR to genotoxic 
insults involves a class of protein kinases, including ATM, 
ATR, and DNA-dependent protein kinases, followed by 
activation of Chk1 and Chk2 kinases that causes temporal 
cell cycle arrest, and promotes assembly of DNA repair 
complexes at the damaged sites on chromosomes [19-21]. 
In vivo activation of Chk1 requires phosphorylation on 
both Ser-345 and Ser-317 [22]. Cell cycle arrest can then 
lead to different cellular programs including senescence, 
apoptosis and mitotic catastrophe [23, 24]. 
Beyond its effects on angiogenesis, axitinib has 
been recently shown to modulate the function of immune 
effector cells that play an important role in the control of 
RCC development, progression and drug response [25,26]. 
RCC exhibits a prominent immune cell infiltrate consisting 
of T cells, dendritic cells (DCs), macrophages and natural 
killer (NK) cells. 
NK cells represent one of the main effectors of 
the immunosurveillance against tumors [27, 28]. NK 
cell activity depends on the interplay between inhibitory 
receptors for major histocompatibility complex (MHC) 
class I molecules and activating receptors, such as 
NKG2D and DNAM-1 that operate in concert to induce 
the elimination of tumor cells [29, 30]. Human NKG2D 
belongs to C-type lectin-like receptor family and 
recognizes MHC I-related molecules MICA/B and ULBPs 
(UL16-binding proteins) [31-33]. NKG2D is expressed 
not only on NK cells, but also on γδ T cells, CD8+ T cells, 
and a subset of CD4+ T cells. The expression of NKG2D 
ligands is largely confined to virus-infected, tumor, 
and stressed cells [31]. DNAM-1 is a transmembrane 
glycoprotein constitutively expressed on the majority of 
T cells, NK cells, and macrophages. DNAM-1 ligands, 
namely nectin-2 (Nec-2, CD112) and the poliovirus 
receptor (PVR, CD155), have been initially described 
as adhesion molecules and only recently they have been 
found on a variety of tumors and virus-infected cells [33-
35]. 
In this study, we demonstrated the ability of axitinib 
treatment to trigger DNA damage response, cell cycle 
arrest and senescence, and mitotic catastrophe in RCC 
cells. In addition, we further evaluated axitinib ability to 
increase NKG2D and DNAM-1 ligand surface expression 
and to enhance NK cell recognition and activity against 
RCC cells.
RESULTS
Axitinib inhibits RCC cell viability in a dose and 
time-dependent manner
We first evaluated the effects of axitinib on cell 
viability in A-498 and Caki-2 RCC lines by performing 
dose-response and time-course analyses (Figure 1). 
Axitinib inhibited the growth of RCC lines, with IC50 
values of 13.6 µM for A-498 and 36 µM for Caki-2 cells 
after 96 h of treatment, indicating that Caki-2 cells are 
more resistant to axitinib-mediated cytotoxic effects. 
The lowest effective dose of axitinib inducing growth 
inhibition (12.5 μM for A-498 and 25 μM for Caki-2 
cells after 96 h treatment) was used for the subsequent 
experiments.
Axitinib triggers DDR associated with oxidative 
DNA damage in RCC cells
To evaluate whether axitinib treatment could 
trigger DDR in RCC cells, we initially investigated the 
presence of γ-H2AX (H2AX), a phosphorylated variant 
of histone 2A that is associated with DNA double-strand 
breaks [36]. Interestingly, western blot analysis revealed 
strong induction of the DNA damage marker in both RCC 
cell lines, being more rapid and sustained in A-498 cells 
(Figure 2A). γ-H2AX induction was accompanied by 
Ser317- and Ser345-Chk1 phosphorylation already after 1 
h exposure to axitinib and persisting at later points only in 
A-498 cells (Figure 2B, 2C). Later at 12 h after treatment, 
a progressive overexpression of p21 that paralleled the 
decline of Ser345- and Ser317-Chk1 activation and Chk1 
protein levels, was mainly observed in A-498 cells (Figure 
2B, 2C). 
In addition, immunofluorescence analysis with 
8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxo-dG), a 
marker of oxidative DNA damage [37], in cells treated 
for different times with axitinib alone or in combination 
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Figure 1: Axitinib inhibits RCC cell viability in a dose and time-dependent manner. A. A-498 and Caki-2 RCC cell lines 
were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± 
SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell lines were cultured for 96 h with different doses of axitinib. 
Cell viability was determined by MTT assay. Data shown are expressed as mean ± SE of three separate experiments. 
Figure 2: Axitinib triggers DDR in RCC cells. A. Western blot analysis and densitometry quantification of H2AX protein levels in 
RCC cells cultured for up to 72 h in the presence of axitinib (12.5 μM in A-498 and 25 μM in Caki-2). H2AX densitometry values were 
normalized to GAPDH used as loading control. Blots are representative of one of three separate experiments, *p < 0.01 treated vs untreated 
cells. B. Western blot analysis of Chk1-Ser345, Chk1-Ser317, Chk1 and p21 protein levels in RCC cells cultured for up to 72 h as above 
described. Blots are representative of one of three separate experiments. C. Quantitative representation of the experiment reported in panel 
B. Chk1 and p21 densitometry values were normalized to GAPDH used as loading control. The Chk1-Ser345 and Chk1-Ser317 protein 
levels were determined with respect to Chk1 levels. For Chk1-Ser345, Chk1-Ser317 and Chk1, the initial protein levels were taken as 1. 
For p21, the maximal p21 protein levels were also taken as 1. 
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with the antioxidant NAC, indicated that axitinib induces 
oxidative DNA damage in a time-dependent manner, being 
more rapid and prominent in A-498 cells (Figure 3A); this 
response was reverted by pre-treatment of RCC cells with 
the antioxidant NAC (Figure 3B).
Axitinib induces G2/M arrest and cell senescence 
in RCC cells
We then evaluated whether axitinib treatment could 
result in changes in cell cycle. Thus, we performed cell 
cycle experiments in the presence of axitinib for 96 h. We 
observed that treatment of RCC cells induced a significant 
decrease of G0/G1 phase cell population already at 6 
h and this decrease was accompanied by a parallel and 
progressive increase of G2/M-phase cell population 
until 72 h (Figure 4A). Again, the axitinib effects were 
more potent in A-498 cells as compared to Caki-2 cells. 
In addition, pre-treatment of RCC cells with NAC 
reverted the axitinib-induced effects on cell cycle at any 
experimental time point tested (Figure 4B, and data not 
shown). 
An accumulation of RCC cells with enlarged and 
flattened morphology was observed at 48 h after axitinib 
treatment by microscopy and biparametric (forward 
scatter, FSS vs side scatter, SSC) cytofluorimetric analysis 
Figure 3: Axitinib triggers oxidative DNA damage in RCC cells. A. Immunofluorescence analysis of 8-oxo-dG in A-498 and 
Caki-2 RCC cells treated with axitinib (12.5 μM and 25 μM, respectively) for different times. Optical Density Units (ODU) were calculated 
on ten random fields. Data shown are representative of one of three separate experiments, *p < 0.01 vs. untreated cells. Bar: 100 μM. 
B. Immunofluorescence analysis of 8-oxo-dG in A-498 cells treated with axitinib 12.5 μM for 60 min and in Caki-2 cells treated with 
axitinib 25 μM for 120 min alone or pretreated with NAC (10 mM for 1 h). ODU were calculated on ten random fields. Data shown are 
representative of one of three separate experiments, *p < 0.01 vs. axitinib treated cells. Bar: 100 μM.
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(Supplementary Figure 1). Since these morphological 
changes are reminiscent of a senescent phenotype, 
we analyzed the presence of senescence-associated 
β-galactosidase (SA-β-gal) activity, in axitinib-treated 
cells [38,39]. Seventy-two hours after axitinib treatment, 
increased levels of SA-β-gal activity were detected in RCC 
cells stained with the fluorescent β-galactosidase substrate, 
C12FDG as determined by flow cytometry. (Figure 5A). 
Recent studies have suggested that reactive oxygen 
species (ROS) generation by anticancer drug treatment can 
stimulate cellular senescence [40]. Thus, we evaluated the 
generation of ROS in RCC cells by flow cytometry using 
the general redox-sensitive fluorescent dye, DCFDA. 
As shown in Figure 5B, axitinib stimulated intracellular 
generation of ROS that was evident at 24 h after exposure, 
being more rapid and sustained in A-498 cells. These 
results were also supported by cytochemical assessment 
of SA-β-gal activity that revealed a significant reduction 
in the percentage of blu-stained axitinib-treated senescent 
cells after pretreatment with NAC (Figure 5C). 
Axitinib induces mitotic catastrophe in RCC cells
Mitotic catastrophe is a non-apoptotic cell death 
resulting from cell cycle arrest and abnormal mitosis, 
usually ending in the formation of large cells with multiple 
micronuclei [41]. Thus we decided to study whether 
axitinib treatment could also result in mitotic catastrophe 
in RCC cells, by assessing the changes in nuclear 
morphology using Hoechst 33258 staining. Increased 
number of micronuclei was observed at 96 h in both 
RCC cell lines (Figure 6A). In addition, by examining 
the expression of α-tubulin, abnormal microtubule 
assembly was found in axitinib-treated RCC cells at 96 
h after treatment (Figure 6B). To further support mitotic 
catastrophe as the mode of death, FITC-conjugated 
Annexin V/PI and cytofluorimetric analysis, agarose gel 
electrophoresis for DNA fragmentation and western blot 
analysis for caspase-3 activity were performed in untreated 
or axitinib-treated cells. Axitinib treatment resulted in an 
increased percentage of cells undergoing necrotic-like 
death (Annexin V-/PI+) and secondary necrosis (Annexin 
V+/PI+) upon drug exposure in both RCC cell lines, being 
Figure 4: Axitinib induces cell cycle arrest in ROS-dependent manner. A. Cell cycle analysis in A-498 cells treated with 
axitinib 12.5 μM and in Caki-2 cells treated with axitinib 25 μM for the indicated times. B. Representative cell cycle distribution in A-498 
and Caki-2 cells pretreated or not with NAC (10 mM for 1 h) before axitinib treatment for 24 h.
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the frequency of dead cells higher and the cell death 
program more advanced in A-498 cells as compared 
to Caki-2 cells (Figure 6C); moreover, neither DNA 
fragmentation (Figure 6D) or caspase-3 activation (Figure 
6E) was evidenced in axitinib-treated RCC cells. 
Taken together, these results indicate that axitinib 
induces cell death in RCC cells through mitotic 
catastrophe.
Axitinib preferentially increases NKG2D ligand 
expression in senescent RCC cells 
Since chemotherapeutic agents through the 
activation of the DDR have been shown to enhance the 
expression of NKG2D and DNAM-1 ligands on human 
multiple myeloma cells in a ROS-dependent manner [18], 
we investigated whether axitinib treatment could modulate 
the expression of the ligands for NKG2D and DNAM-1 
activating NK receptors on A-498 and Caki-2 RCC lines, 
and the involvement of ROS signaling in this event. To this 
aim we firstly evaluated the basal expression of NKG2D 
(MICA, MICB, ULBP1, 2, 3, 5, 6) and DNAM-1 (PVR 
and nectin-2) ligands on A-498 and Caki-2 RCC cells by 
immunofluorescence and cytofluorimetric analysis. Both 
cell lines constitutively express MICA and ULBP family 
NKG2D ligands, and PVR and nectin-2 DNAM-1 ligands, 
but with a different profile (Figure 7A). Seventy-two 
hour treatment of RCC cells with axitinib induced MICB 
expression in A-498 cells, and increased the expression of 
ULBP1 and MICA in Caki-2 cells, respectively (Figure 
7A). In addition, down-regulation of nectin-2 and PVR 
DNAM-1 ligands was observed in Caki-2 cells upon drug 
exposure (Figure 7A). Moreover, we found that MICB 
was preferentially expressed on FDG-positive A-498 
cells undergoing senescence as demonstrated by double 
immunofluorescence and flow cytometry (Figure 7B). 
We next investigated the expression of MICB, 
MICA and ULBP1 on PI- A-498 and Caki-2 RCC cells, 
respectively, in the presence of anti-oxidant NAC. 
Exposure of RCC cells to NAC resulted in complete 
inhibition of MICB and ULBP1 expression in A-498 and 
Caki-2 cells, respectively (Figure 8A and 8B), whereas 
NAC pretreatment did not significantly reduce axitinib-
induced increase of MICA expression on Caki-2 cells that 
exhibited a weaker oxidative stress response.
Figure 5: Axitinib induces cellular senescence in RCC cells in a ROS-dependent manner. A. Representative flow cytometric 
profiles of RCC cells untreated or treated with axitinib for 72 h, then stained with C12FDG, a fluorogenic substrate for SA-β-galactosidase 
before analysis. Data represent the percentage of positive cells. B. ROS generation in RCC cell lines treated with axitinib for the indicated 
times. Cells were stained with DCFDA before flow cytometric analysis. Data are expressed as percentage of DCFDA positive cells with 
respect to untreated cells; *p < 0.01 treated vs. untreated cells. C. Cellular senescence was assessed in A-498 cells treated with axitinib 12.5 
μM and in Caki-2 cells treated with axitinib 25 μM for 72 h, with or without pretreatment with NAC 10 mM for 1 h, by detection of SA-β-
galactosidase activity using cytochemistry. Arrows indicate blue-stained positive cells. Graph represents the percentage of β-galactosidase+ 
cells calculated on ten random fields. Data shown are representative of one of three separate experiments, *p < 0.01 vs. untreated cells. #p 
< 0.01 vs. axitinib-treated cells. Bar: 25 μM.
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Enhanced NK cell degranulation upon interaction 
with axitinib-treated A-498 RCC cells
Based on these findings, we evaluated whether 
axitinib would increase NK cell degranulation upon 
interaction with drug-treated RCC cells. The expression 
of the lysosomal marker CD107a, which correlates 
with NK cell cytotoxicity [42] was evaluated by 
immunofluorescence and flow cytometry analysis by 
gating on CD56+ human peripheral blood NK cells 
contacting treated or untreated RCC cells used as target. 
The expression of CD107a on NK cells from two different 
healthy donors contacting axitinib treated-RCC target 
cells, revealed that drug-treated A-498 RCC cells more 
efficiently triggered NK cell degranulation as compared 
to untreated cells, and this enhancement is completely 
blocked by NAC pretreatment, in parallel with inhibition 
of MICB induction (Figure 9). Conversely, no significative 
changes in CD107a expression were observed on NK cells 
contacting axitinib-treated Caki-2 cells (Supplementary 
Figure 2), likely attributable to the lower responsiveness 
of these cells to the axitinib-exerted activity. 
Figure 6: Axitinib induces mitotic catastrophe in RCC cells. A. Nuclei of RCC cells untreated or treated with axitinib for 96 h 
were stained with Hoechst 33258 and then analyzed on ten random fields. Cells were observed under a fluorescence microscope. Bar: 50 
μM. B. Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM. 
C. RCC cells were cultured for 96 h with axitinib. Flow cytometric analysis was performed on treated cells by Annexin V-FITC and PI 
double-staining. Data represent the percentage of PI and/or Annexin V positive cells. D. Representative agarose gel electrophoresis of DNA 
extracts obtained from untreated or axitinib treated cells at 96 h for assessment of DNA fragmentation. E. Representative immunoblot of 
caspase-3 in RCC cells treated as above described.
Oncotarget36252www.impactjournals.com/oncotarget
Figure 7: Modulation of NKG2D and DNAM-1 ligand expression on the RCC cell lines by axitinib treatment. A. MICB, 
MICA, ULBP1, ULBP2, 5, 6 and ULBP3, PVR and nectin-2 surface expression was analyzed by flow cytometry on RCC cells treated for 
72 h with axitinib or untreated. Light lines represent ligand expression in untreated cells, dark lines represent ligand expression in axitinib-
treated RCC cells, whereas gray histogram isotype controls. MFI, mean fluorescence intensity. B. Representative dot plots illustrating the 
double fluorescence MICB-APC/C12FDG in A-498 RCC cells treated as above described. Numbers represent the percentage of cells in each 
quadrant. Results are representative of 1 of 3 independent experiments.
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DISCUSSION
TKIs and in particular axitinib have been recently 
approved for the treatment of advanced mRCC, mainly 
for their anti-angiogenic properties. Herein, we provide 
evidence indicating that axitinib anti-tumor activity can 
be also the result of its ability to induce DDR, cellular 
senescence and mitotic catastrophe, and to enhance the 
recognition of RCC cells by innate immune effector cells 
through the modulation of activating ligands. 
In particular, we found that treatment of RCC with 
suboptimal doses of axitinib triggers a DDR evidenced 
by increased levels of H2AX, Ser317- and Ser345-Chk1 
phosphorylation and DNA oxidation, leading to cell cycle 
arrest at G2/M phase and cellular senescence. At later 
time points, overexpression of the cell cycle inhibitor p21 
was observed and paralleled decreased levels of Chk1 
activation and depletion. In this regard, reactivation of a 
senescence program in PC-3 prostate cancer cells upon a 
retrovirus-mediated transduction of p21, was described to 
suppress Chk1 activation [43].
We also investigated the involvement of redox 
signaling on the ability of axitinib treatment to induce 
cellular senescence in A-498 and Caki-2 RCC cells. We 
found that drug exposure increases ROS generation and 
induces the DNA oxidation, whereas pretreatment with the 
antioxidant agent NAC results in impaired cell cycle arrest 
and decreased percentage of SA-β-gal positive cells. 
Similarly to our study, treatment of gastric cancer 
cells with axitinib was reported to induce a senescent 
phenotype characterized by increased cell size, expression 
of SA-β-galactosidase and arrest in G2 cell cycle phase 
Figure 8: ROS-dependent axitinib-induced increase of NKG2D ligand expression in the RCC cell lines. A. Increase 
of MICB surface expression was analyzed by flow cytometry on A-498 RCC cell line treated with axitinib for 72 h with or without 
pretreatment with NAC 10 mM for 1 h. Representative dot plots illustrate the double fluorescence ligands-APC/PI. Numbers represent the 
percentage of cells in each quadrant. Data are representative of 1 of 4 independent experiments. B. Increase of MICA and ULBP1 surface 
expression was analyzed by flow cytometry on Caki-2 RCC cells treated with axitinib for 72 h with or without pretreatment with NAC 10 
mM for 1 h. Representative dot plots illustrate the double fluorescence ligands-APC/PI. Numbers represent the percentage of cells in each 
quadrant. Data are representative of 1 of 4 independent experiments.
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[44]. 
Cell cycle arrest and senescence are often associated 
with mitotic catastrophe. Chk1, the kinase that regulates 
the G2/M checkpoint, is also particularly important 
for preventing mitotic catastrophe in cells treated with 
DNA-damaging agents [45-47]. Mitotic catastrophe has 
been described as the main form of cell death induced by 
anticancer drugs [48, 49]. Similarly to necrosis, mitotic 
catastrophe shows early loss of plasma membrane 
integrity, with large cells containing uncondensed 
chromosomes [50]. Treatment with axitinib caused an 
increased frequency of cells undergoing necrotic-like 
death and secondary necrosis as well as mitotic catastrophe 
characterized by multinucleation, abnormal microtubule 
assembly, early membrane permeabilization and absence 
of apoptotic features such as caspase 3 activation and 
DNA fragmentation.
Our study provides also evidence that axitinib 
treatment increases the surface expression of stress-
induced ligands recognised by innate immune effector 
cells.
Up-regulation of stress-inducible NK-cell activating 
ligands is preferentially associated with the onset of a 
senescent phenotype and arrest in the G2 phase of the cell 
cycle [51]. Our findings demonstrate that A-498 and Caki-
2 RCC cells constitutively express, although at different 
levels, several NKG2D and DNAM-1 ligands. Axitinib 
treatment induced MICB expression in A-498 RCC cells 
and increased ULBP1 and MICA expression in Caki-2 
cells. In addition in these latter cells, significative down-
regulation of the DNAM-1 ligand PVR was observed.
We also demonstrated that induction of MICB on 
A-498 RCC cells and ULBP-1 on Caki-2 cells requires 
ROS signaling as ligand up-regulation was susceptible to 
NAC pretreatment. By contrast, in Caki-2 cells pretreated 
with NAC, no reversal of axitinib-induced increase of 
MICA expression was evident. Moreover, in accordance 
with previous evidence indicating that NKG2D and 
DNAM-1 ligand are expressed on tumor cells with 
senescent phenotype upon treatment with genotoxic 
agents [52], we found a preferential expression of MICB 
on axitinib-treated senescent A-498 RCC cells. Like 
axitinib, other TKIs such as sorafenib and sunitinib have 
been described to induce the expression of MICA/B in 
nasopharyngeal carcinoma cells [53], but their association 
with a senescent phenotype was not reported. 
As far as the mechanisms underlying axitinib-
induced MICB expression, a role for Signal transducer 
and activator of transcription 3 (STAT3) inhibition can be 
envisaged based on the recent evidences demonstrating 
that axitinib can stimulate anti-tumor immunity by down-
regulating the STAT3 expression in Renca RCC cells 
[54], and MICA/B expression on cancer cells induced 
by genotoxic stress is enhanced by inhibition of STAT3 
activity [55]. 
Our results also show increased degranulation 
activity in NK cells contacting axitinib-treated A-498 but 
not Caki-2 RCC cells. The failure of axitinib-treated Caki-
2 cells to promote NK cell degranulation as compared 
to A-498 RCC cells may depend on the less potent and 
sustained DDR induced by axitinib in this tumor cell 
line. In addition, this result may be related to the drug-
induced down-regulation of DNAM-1 ligand expression 
observed in these cells leading to lack of cooperative 
signals required for the triggering of NK cell cytotoxic 
program [56].
Figure 9: Enhanced NK cell degranulation upon interaction with axitinib-treated A-498 RCC cells is ROS-dependent. 
A-498 RCC cells were treated with axitinib 12.5 μM for 72 h with or without pretreatment with NAC 10 mM for 1 h, and then incubated 
with freshly isolated human peripheral blood NK cells from two different healthy donors at 1:1 ratio for 2 h. Results are expressed as 
percentage of CD107a+ NK cells.
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Collectively, our findings are consistent with 
previous evidence describing RCC susceptibility to 
NK cell-mediated cytotoxicity, and the presence of a 
high frequency of NK cells in the lymphocytic infiltrate 
of RCC predicting a better prognosis [57]. Moreover, 
interleukin-2 (IL-2) in combination with infusion of IL-2-
activated NK and LAK cells has been widely employed as 
immunotherapeutic approach for RCC patients [58]. 
Based on these findings, the use of axitinib 
in sequential or combined strategies with other 
immunotherapic approaches, such as anti-programmed 
death-1 (PD-1) or PD-ligand 1 (PD-L1) agents, should 
be tested in prospective clinical trials. At this regard, a 
phase I study is in course to assess the safety of axitinib 
in combination with avelumab (MSB0010718C), an 
anti-PD-L1 antibody, in patients with advanced RCC 
(NCT02493751).
Taken together, our study first demonstrate that 
axitinib not only inhibits angiogenesis, but it can exert 
direct genotoxic effects on RCC cells by inducing cell 
cycle arrest and mitotic catastrophe, and activating a 
cellular senescence program. This direct cytotoxic effect 
of axitinib in RCC cells may partially explain the relevant 
gastrointestinal and hematologic toxicity of this agent 
[12].
In addition, axitinib can also display an immune-
mediated antitumor activity by promoting NK cell-
mediated recognition and elimination of RCC through 
the regulation NK activating ligand expression. A better 
dissection of the functions of immune cells in RCC 
microenvironment and of the immune-modulatory effects 
of TKIs will be crucial to optimize immunotherapeutic 
approaches in RCC advanced patients. 
MATERIALS AND METHODS
Cell line culture and treatment
Human kidney cancer (Caki-2 and A-498) cell 
lines were purchased from Cell bank Interlab Cell 
Line Collection (ICLC, Italy) and cultured at 37°C in 
a humidified atmosphere of 5% CO2. Caki-2 cells were 
cultured in McCoy’s 5a medium (Lonza Bioresearch, 
Basel, Switzerland) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS), 2mM L-glutamine 
and 100 IU/ml of penicillin, 100 µg of streptomycin 
(Lonza). A-498 cells were cultured in EMEM medium 
(Lonza) supplemented with 10% (v/v) heat-inactivated 
FBS 2mM L-glutamine and 100 IU/ml of penicillin, 100 
µg of streptomycin and 1 mM sodium pyruvate (Lonza). 
A-498 and Caki-2 cells were treated with different 
doses of axitinib (1, 2.5, 5.0, 10.0, 12.5, 25.0, 50.0 and 100 
µM) for different times. In some experiments Caki-2 and 
A-498 cells were pretreated for 1 h with 10 mM of NAC, 
before axitinib treatment.
Reagents
Axitinib ((Inlyta®) was kindly provided by Pfizer 
(New York, NY, USA). The following mouse monoclonal 
allophycocyanin (APC)-conjugated antibodies (Abs) 
were used: anti-MICB, anti-MICA, anti-PVR, anti-
ULBP1, anti-ULBP 2,5,6, anti-ULBP3 and anti-nectin-2 
(R&D Systems, Abingdon, United Kingdom). APC-
conjugated goat affinity purified F(ab’)2 fragment 
to mouse IgG1, IgG2a, IgG2b were purchased from 
Jackson ImmunoResearch Laboratories (West Grove, 
PA). Mouse anti-α-tubulin and anti-p21 antibodies 
were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). Rabbit anti-H2AX, anti-Chk1-Ser345, 
anti-Chk1-Ser317, anti-Chk1 and anti-caspase-3 were 
purchased from Cell Signaling Technology (Danvers, 
MA). The following secondary antibodies were used: 
horseradish peroxidase (HRP)-conjugated sheep anti-
mouse IgG and HRP-conjugated donkey anti-rabbit 
IgG (GE Healthcare, Munich, Germany). Annexin 
V-FITC was purchased from eBioscience (Hatfield, 
UK). 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxo-dG) 
MAb was purchased from Trevigen (Gaithersburg, MD, 
USA). Goat anti-mouse (GAM) Alexa Fluor 594 and 
5-dodecanoylaminofluorescein di-β-D- galactopyranoside 
(C12FDG) were from Invitrogen (San Diego, CA, USA). 
Bafilomycin A1, dimethyl sulfoxide (DMSO, used as 
vehicle), Hoechst 33258, propidium iodide (PI, 1 μg/
ml), ribonuclease A, 5-bromo-4-chloro-3-indolyl β-D-
galactopyranoside (X-Gal), N-acetyl-L-cysteine (NAC), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH)-peroxidase were from Sigma 
Aldrich (St. Louis, USA). 
MTT assay 
The colorimetric MTT assay was used to evaluate 
the cell viability. Three x105 RCC cells/ml were seeded 
into 96-well plates and cultured with different doses of 
axitinib for up to 96 h. At the end of treatment, 0.8 mg/
ml of MTT was added to the samples and incubated for 
3 h. Then the supernatants were discarded and coloured 
formazan crystals dissolved with 100 μl/well of DMSO, 
were read by an enzyme-linked immunosorbent assay 
reader (BioTek Instruments, Winooski, USA). Four 
replicates were used for each treatment. 
Cell cycle analysis
Three x105 RCC cells/ml were treated with vehicle 
or axitinib, alone or in combination with NAC, for up 
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to 72 h. Cells were collected and fixed in 70% ethanol 
and then washed with staining buffer (PBS, 2% FBS and 
0.01% NaN3). Next, the cells were treated with 100 μg/
ml ribonuclease A solution, incubated for 30 min at 37°C, 
stained for 30 min at room temperature with PI 20 μg/
ml and finally analysed by flow cytometry using linear 
amplification.
Western blot analysis
Cells were lysed in lysis buffer (1M Tris pH 7.4, 1 
M NaCl, 10 mM EGTA, 100 mM NaF, 100 mM Na V0, 
100 mM phenylmethylsulfonyl fluoride, 2% deoxycholate, 
100 mM EDTA, 10% Triton X-l00, 10% glycerol, 10% 
SDS, 0.1 M Na4 P2 07) containing protease inhibitor 
cocktail (Sigma-Aldrich) by using a Mixer Mill MM300 
(Qiagen, Hilden, Germany). Lysates were separated on 
SDS polyacrylamide gel and transferred onto Hybond-C 
extra membranes (GE Healthcare). Membrane were 
incubated overnight at 4°C in primary Abs (anti-caspase 3 
1:100; anti-H2AX 1:1000, anti-Chk1-Ser345 1:1000, anti-
Chk1-Ser317 1:1000, anti-Chk1 1:1000, anti-p21 1:300), 
followed by the incubation (room temperature, 1 h) with 
HRP-conjugated anti-rabbit or anti-mouse secondary Abs. 
Peroxidase activity was visualized with the LiteAblot 
®PLUS (EuroClone, Milan, Italy) kit and densitometric 
analysis was carried out by a Chemidoc using the Quantity 
One software (Bio-Rad). 
Senescence analysis
We performed the senescence analysis by both 
microscope and flow cytometry. RCC cells were 
treated with axitinib or vehicle before performing the 
senescence-associated β-galactosidase (SA-β-Gal) assay. 
Cells were then fixed for 5 min at room temperature 
in 3% formaldehyde and incubated overnight at 37°C 
without CO2 with fresh SA-β-Gal stain solution: 1 
mg/mL 5-bromo-4-chloro-3-indolyl β-D-galactoside 
(X-Gal), 150 mM NaCl, 2 mM MgCl2, 40 mM citric 
acid, 5 mM sodium phosphate (pH 6.0), 5 mM potassium 
ferrocyanide, and 5 mM potassium ferricyanide. Senescent 
cells were identified as blue-stained cells by standard light 
microscopy. Photographs were acquired and analyzed 
by an Olympus BX51 microscope (Hamburg, Germany) 
using magnification 40x.
Relatively to flow cytometry, we performed the 
assay using the fluorogenic substrate C12FDG. Drug-
treated cells were incubated 1 h at 37°C and 5% CO2 
with 100 nM bafilomycin A1 in culture medium to induce 
lysosomal alkalinization at pH 6 and, then, for 1 h with 33 
μM C12FDG. Samples were immediately analyzed using 
FACScan cytofluorimeter using the CellQuest software. 
The C12-fluorescein signal was measured on the FL-1 
detector, and β-galactosidase activity was estimated using 
the median fluorescence intensity (MFI) of the population.
Annexin V and PI staining
Cell death was evaluated using Annexin V-FITC 
and PI staining followed by biparametric FACS analysis. 
Three x105 A-498 and Caki-2 RCC cells were treated with 
axitinib or with vehicle for up to 96 h. The percentage of 
positive cells determined over 10,000 events was analyzed 
on a FACScan cytofluorimeter using the CellQuest 
software. 
DNA fragmentation assay
RCC cells were treated as above described for up 
to 96 h, and genomic DNA was extracted using a DNA 
extraction kit (Qiagen). The purified samples were then 
subjected to electrophoresis on a 1.25% agarose gel, and 
DNA was stained with ethidium bromide. Ultraviolet 
spectroscopy at 302 nm was used to obtain the results.
Reactive Oxygen Species (ROS) production
Cells were cultured for up to 96 h with axitinib or 
vehicle. Cells were washed with PBS, pulsed with DCFDA 
for 10 min at 37°C, 5% CO2, and analyzed by FACScan 
cytofluorimeter using the CellQuest software.
α-Tubulin and nuclei staining 
Cells cultured as above described were fixed in 2% 
formaldehyde and 0.5% triton X-100 for 10 min at room 
temperature and then in 4% formaldehyde and 0.5% triton 
X-100 for 10 min. To examine the expression of α-tubulin, 
fixed cells were permeabilized in 0.1% Tween-20/3% 
BSA, and stained with mouse anti-α-tubulin antibody 
(1:50). Cells were further incubated with Alexa-594-
conjugated GAM (1:100). For nuclei analysis, cells were 
fixed in Carnoy’s fixative (1:3 glacial acetic acid: absolute 
methanol) and stained with 0,05 μg/ml Hoechst 33258. 
Stained cells were examined by using the Olympus BX51 
microscope.
Immunofluorescence and microscopic analysis
For immunofluorescence analysis, RCC cells were 
fixed with 1:1 MeOH, acetone for 20 min at -20°C and 
labeled with anti-8-hydroxyguanine (8-oxo-dG) antibody 
(1:250) diluted in 1X PBS containing 1% BSA, 0.01% 
Tween 20 at 4°C o/n in a humidified chamber according to 
manufacturer’s instructions. Cells were further incubated 
with Alexa-594-conjugated GAM (1:100). Photographs 
were acquired and analyzed by an Olympus BX51 
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microscope.
Cytofluorimetric analysis
NKG2D and DNAM-1 ligand surface 
expression on Caki-2 and A-498 cells was analyzed by 
immunofluorescence staining using anti-MICA, anti-
MICB, anti-ULBP1/2,5,6/3, anti-PVR or anti-nectin-2 
APC-conjugated mAbs or relative APC-conjugated IgG 
isotypes according to manufacturer’s instructions. In 
some experiments, RCC cells were double stained with 
anti-MICB APC-conjugated mAb and C12FDG or with 
anti-MICB, anti-MICA, anti-ULBP1 APC-conjugated 
mAbs and PI. Fluorescence was analyzed by FACScan 
cytofluorimeter using the CellQuest software.
Degranulation assay 
NK cell-mediated cytotoxicity was evaluated using 
the degranulation lysosomal marker CD107a as described 
[42]. As source of effector cells freshly purified NK cells 
were used. Peripheral blood mononuclear cells (PBMC) 
were separated from buffy coats of healthy donors 
by Lymphoprep (Nycomed, Oslo, Norway) gradient 
centrifugation. Freshly isolated NK cells were then isolated 
from PBMC by negative selection using a magnetically 
activated cell sorter NK isolation kit (Miltenyi Biotec, 
Bologna, Italy). This purification protocol resulted in 
a purity of more than 95% of negatively selected NK 
cells. After 72 h treatment with axitinib, RCC cells were 
incubated with NK cells at effector:target (E:T) ratios 
of 1:1 in a flat-bottom 96-well tissue culture plate in 
complete medium. In some experiments axitinib-treated 
where exposed to NAC (10 mM, for 1 h). The plates were 
then incubated at 37 °C in a 5% CO2 atmosphere for 2 h. 
Thereafter, cells were incubated with anti-CD107a/APC 
(or cIgG/APC) for 45 min at 4 °C. Cells were also stained 
with anti-CD56/PE to gate NK cell population. 
Statistical analysis 
The data presented represent the mean and standard 
deviation (SD) of at least 3 independent experiments. The 
statistical significance was determined by Student’s t-test 
and by one way ANOVA; *,# p < 0.01. The statistical 
analysis of IC50 levels was performed using Prism 5.0a 
(Graph Pad).
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